A New Therapeutic Strategy Targeting Protein Deacetylation for Spinal Cord Injury

Area of Science:

• Biochemistry
• Neuroscience
• Proteomics

Background:

• Lysine acetylation is a crucial post-translational modification regulating biological processes.
• The role of lysine acetylation in spinal cord injury (SCI) is not well understood.
• Investigating acetylation patterns in SCI is essential for understanding injury mechanisms.

Purpose of the Study:

• To conduct a proteomic-scale investigation of acetylation events in injured spinal cords.
• To evaluate the therapeutic potential of promoting acetylation in mitigating SCI.
• To identify key pathways and proteins involved in SCI-related acetylation changes.

Main Methods:

• Proteomic analysis to identify differentially acetylated peptides in SCI tissues.
• Functional enrichment analysis (Gene Ontology) and pathway analysis (Kyoto Encyclopaedia of Genes and Genomes).
• In vivo evaluation of glycerol triacetate (GTA) as an acetylation-promoting therapeutic agent in a SCI model.

Main Results:

• Identified 268 differentially acetylated peptides, with 141 peptides showing decreased acetylation in SCI.
• Functional analysis revealed involvement of acetylated proteins in cellular and metabolic processes, including cGMP-PKG and HIF-1 signaling pathways.
• GTA treatment improved functional recovery (Basso-Beattie-Bresnahan scores), histological outcomes, and reduced neuronal apoptosis and inflammation in SCI models.

Conclusions:

• Protein deacetylation appears to be critical in the secondary injury phase of SCI.
• Promoting acetylation via GTA demonstrates a significant therapeutic effect in mitigating SCI.
• This study provides novel insights into the spinal cord acetylproteome and potential therapeutic targets for SCI treatment.